Robert F. Kennedy Jr. Takes Charge at HHS
Robert F. Kennedy Jr., the newly appointed secretary of the U.S. Department of Health and Human Services, is swiftly implementing his agenda. One of his first commitments to senators was a promise of “radical transparency,” which he is making good on by promptly responding to congressional inquiries regarding federal policies during the COVID-19 pandemic. Compared to the previous administration, which largely ignored these requests for four years, this feels like a significant shift.
Kennedy and his team are also reevaluating government guidelines on COVID-19 vaccines. Their approach is more focused on performing a rational risk-benefit analysis, and they have dismissed the 17 members of the Advisory Committee on Immunization Practices, who were appointed during the Biden administration. This committee is responsible for making recommendations to the Centers for Disease Control and Prevention (CDC).
After a challenging four-year period, changes to the federal policy on COVID vaccine recommendations are essential. The disparities in risks associated with COVID-19—especially concerning mortality—versus the benefits of vaccination vary significantly by age and the presence of underlying health issues. CDC statistics indicate that from January 1, 2020, to April 30, 2025, there were 1,227,616 deaths attributed to COVID-19. Of these, over half were among those aged 75 and older, suggesting that nearly 94% of recorded COVID deaths occurred in Americans who were 50 years or older.
Looking at the younger segments of the population illustrates a stark contrast. During the same period, only 20,554 (about 1.67%) of deaths occurred among individuals aged 30 to 39, with even fewer among those aged 18 to 29 (7,394 deaths, or 0.06%) and younger age groups. This discrepancy highlights that older and medically vulnerable individuals face significantly higher risks from COVID-19, making the vaccine’s benefits—such as preventing hospitalization and death—more pronounced for them.
However, the previous official guidelines did not reflect this nuanced risk-benefit analysis. A discussion in The New England Journal of Medicine, authored by Marty Makary and Dr. Vinay Prasad, pointed out that the approach taken during the Biden administration was overly broad. They noted that while many other wealthy nations focus vaccination recommendations on older adults or high-risk groups, U.S. policies seemed to apply a one-size-fits-all model.
Both experts anticipate that continued COVID-19 vaccinations would be suitable for those aged over 65 and individuals with certain health conditions. However, they suggest that for healthy people aged 6 to 64, vaccination should be contingent on clinical trial results and robust ongoing monitoring. In line with this shift, Kennedy has announced the cancellation of CDC recommendations for COVID vaccines in healthy young children and pregnant women.
This represents a major change in government policy, aligning more closely with practices seen in Europe. Despite previous assurances of the vaccines’ safety, mounting evidence has surfaced suggesting that adverse reactions may be more common than previously acknowledged, including conditions like myocarditis and various neurological issues.
A Senate testimony in May 2025 confirmed instances where COVID vaccines were linked to deaths and highlighted the flaws in vaccine safety monitoring. While the government’s Vaccine Adverse Events Reporting System is based on self-reported data, it has captured a troubling mortality rate associated with COVID vaccinations that far exceeds that of other vaccines.
This new focus on the distinct impacts of COVID-19, as well as the effectiveness and safety of vaccines, marks a notable departure from past policies. For context, in 2021, the Biden administration stated that vaccines would prevent infection, downplaying natural immunity, and labeled the pandemic as primarily affecting the unvaccinated—a depiction that did not align with the experiences of many.
These past actions have severely eroded public trust in both the vaccines and health officials, contributing to a growing hesitancy towards vaccinations overall. The previous administration often overlooked important evidence regarding adverse vaccine reactions, an accountability gap that Kennedy is aiming to close.
Kennedy’s commitment to transparency is backed by his recent release of 2,473 pages of documents to Senator Ron Johnson, revealing alarming information about myocarditis cases among younger populations reported from Israel in early 2021. Despite having enough data to caution the public about these risks, the Biden administration failed to communicate these dangers effectively.
In recognizing the potential dangers of specific medications, the FDA implements “black box” warnings, alerting users to serious injury risks associated with drugs like antidepressants and opioids. Given the emerging data, a similar labeling for mRNA COVID vaccines may be in order.
Kennedy has initiated a fresh approach, which includes removing individuals connected to the previous administration from key advisory roles. Still, the path ahead requires extensive reforms. The Heritage Foundation has provided a roadmap of 21 actions that Kennedy and his new team can take to ensure stronger accountability in public health decisions. This includes safeguarding scientific debate, improving transparency on vaccine components, and minimizing conflicts of interest within public health.
Kennedy stands at a pivotal moment to revitalize public health agencies, clarify their roles, and restore trust in these institutions as the nation prepares for future health crises. Let’s hope for the best.
